Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans

Reference

• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7:1401 - 13; http://dx.doi.org/10.1517/14712598.7.9.1401; PMID: 17727329
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226 - 34; http://dx.doi.org/10.1038/nrd2804; PMID: 19247305
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs JB, et al. High resolution mapping of the binding site on human IgG1 for Fc γ RI, Fc γ RII, Fc γ RIII, and FcRn and design of IgG1 variants with improved binding to the Fc γ R. J Biol Chem 2001; 276:6591 - 604; http://dx.doi.org/10.1074/jbc.M009483200; PMID: 11096108
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34 - 47; http://dx.doi.org/10.1038/nri2206; PMID: 18064051
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108:12669 - 74; http://dx.doi.org/10.1073/pnas.1108455108; PMID: 21768335
   PubMed Web of Science ®Google Scholar
• Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17:176 - 80; http://dx.doi.org/10.1038/6179; PMID: 10052355
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007; 17:104 - 18; http://dx.doi.org/10.1093/glycob/cwl057; PMID: 17012310
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck RG, O’Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733 - 40; http://dx.doi.org/10.1074/jbc.M202069200; PMID: 11986321
   PubMed Web of Science ®Google Scholar
• Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 2008; 99:652 - 65; http://dx.doi.org/10.1002/bit.21598; PMID: 17680659
   PubMed Web of Science ®Google Scholar
• Wright A, Morrison SL. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 1998; 160:3393 - 402; PMID: 9531299
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466 - 73; http://dx.doi.org/10.1074/jbc.M210665200; PMID: 12427744
   PubMed Web of Science ®Google Scholar
• Mori K, Kuni-Kamochi R, Yamane-Ohnuki N, Wakitani M, Yamano K, Imai H, et al. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol Bioeng 2004; 88:901 - 8; http://dx.doi.org/10.1002/bit.20326; PMID: 15515168
   PubMed Web of Science ®Google Scholar
• Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris.. Nat Biotechnol 2006; 24:210 - 5; http://dx.doi.org/10.1038/nbt1178; PMID: 16429149
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Bobrowicz P, Bobrowicz B, Davidson RC, Li H, Mitchell T, et al. Production of complex human glycoproteins in yeast. Science 2003; 301:1244 - 6; http://dx.doi.org/10.1126/science.1088166; PMID: 12947202
   PubMed Web of Science ®Google Scholar
• Stanley P. Lectin-resistant CHO cells: selection of new mutant phenotypes. Somatic Cell Genet 1983; 9:593 - 608; http://dx.doi.org/10.1007/BF01574260; PMID: 6623313
   PubMedGoogle Scholar
• Wileman TE, Lennartz MR, Stahl PD. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. Proc Natl Acad Sci U S A 1986; 83:2501 - 5; http://dx.doi.org/10.1073/pnas.83.8.2501; PMID: 3458213
   PubMed Web of Science ®Google Scholar
• Schlesinger PH, Doebber TW, Mandell BF, White R, DeSchryver C, Rodman JS, et al. Plasma clearance of glycoproteins with terminal mannose and N-acetylglucosamine by liver non-parenchymal cells. Studies with beta-glucuronidase, N-acetyl-beta-D-glucosaminidase, ribonuclease B and agalacto-orosomucoid. Biochem J 1978; 176:103 - 9; PMID: 728098
   PubMed Web of Science ®Google Scholar
• Wright A, Morrison SL. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 1994; 180:1087 - 96; http://dx.doi.org/10.1084/jem.180.3.1087; PMID: 8064227
   PubMed Web of Science ®Google Scholar
• Chen W, Stanley P. Five Lec1 CHO cell mutants have distinct Mgat1 gene mutations that encode truncated N-acetylglucosaminyltransferase I. Glycobiology 2003; 13:43 - 50; http://dx.doi.org/10.1093/glycob/cwg003; PMID: 12634323
   PubMed Web of Science ®Google Scholar
• Wright A, Sato Y, Okada T, Chang KH, Endo T, Morrison SL. In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure. Glycobiology 2000; 10:1347 - 55; http://dx.doi.org/10.1093/glycob/10.12.1347; PMID: 11159927
   PubMed Web of Science ®Google Scholar
• Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 2009; 19:240 - 9; http://dx.doi.org/10.1093/glycob/cwn120; PMID: 18974198
   PubMed Web of Science ®Google Scholar
• Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949 - 59; http://dx.doi.org/10.1093/glycob/cwr027; PMID: 21421994
   PubMed Web of Science ®Google Scholar
• Inoue T, Yoshida T, Ichishima E. Molecular cloning and nucleotide sequence of the 1,2-α-D-mannosidase gene, msdS, from Aspergillus saitoi and expression of the gene in yeast cells. Biochim Biophys Acta 1995; 1253:141 - 5; http://dx.doi.org/10.1016/0167-4838(95)00195-6; PMID: 8519794
   PubMed Web of Science ®Google Scholar
• Ichishima E, Taya N, Ikeguchi M, Chiba Y, Nakamura M, Kawabata C, et al. Molecular and enzymic properties of recombinant 1, 2-α-mannosidase from Aspergillus saitoi overexpressed in Aspergillus oryzae cells. Biochem J 1999; 339:589 - 97; http://dx.doi.org/10.1042/0264-6021:3390589; PMID: 10215597
   PubMed Web of Science ®Google Scholar
• Pacis E, Yu M, Autsen J, Bayer R, Li F. Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform. Biotechnol Bioeng 2011; 108:2348 - 58; http://dx.doi.org/10.1002/bit.23200; PMID: 21557201
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443 - 6; http://dx.doi.org/10.1038/74704; PMID: 10742152
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MHJ. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115:807 - 11; http://dx.doi.org/10.1046/j.1365-2141.2001.03166.x; PMID: 11843813
   PubMed Web of Science ®Google Scholar
• Clark EA, Ledbetter JA. How does B cell depletion therapy work, and how can it be improved?. Ann Rheum Dis 2005; 64:Suppl 4 iv77 - 80; http://dx.doi.org/10.1136/ard.2005.042507; PMID: 16239394
   PubMedGoogle Scholar
• Correia IR. Stability of IgG isotypes in serum. MAbs 2010; 2:1 - 12; http://dx.doi.org/10.4161/mabs.2.3.11788; PMID: 20065628
   PubMed Web of Science ®Google Scholar
• Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010; 70:4481 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-09-3704; PMID: 20484044
   PubMed Web of Science ®Google Scholar
• Lal A, Pang P, Kalelkar S, Romero PA, Herscovics A, Moremen KW. Substrate specificities of recombinant murine Golgi α1, 2-mannosidases IA and IB and comparison with endoplasmic reticulum and Golgi processing α1,2-mannosidases. Glycobiology 1998; 8:981 - 95; http://dx.doi.org/10.1093/glycob/8.10.981; PMID: 9719679
   PubMed Web of Science ®Google Scholar
• Tremblay LO, Herscovics A. Characterization of a cDNA encoding a novel human Golgi α 1, 2-mannosidase (IC) involved in N-glycan biosynthesis. J Biol Chem 2000; 275:31655 - 60; http://dx.doi.org/10.1074/jbc.M004935200; PMID: 10915796
   PubMed Web of Science ®Google Scholar
• Porwoll S, Fuchs H, Tauber R. Characterization of a soluble class I α-mannosidase in human serum. FEBS Lett 1999; 449:175 - 8; http://dx.doi.org/10.1016/S0014-5793(99)00422-6; PMID: 10338126
   PubMed Web of Science ®Google Scholar
• Gonzalez DS, Karaveg K, Vandersall-Nairn AS, Lal A, Moremen KW. Identification, expression, and characterization of a cDNA encoding human endoplasmic reticulum mannosidase I, the enzyme that catalyzes the first mannose trimming step in mammalian Asn-linked oligosaccharide biosynthesis. J Biol Chem 1999; 274:21375 - 86; http://dx.doi.org/10.1074/jbc.274.30.21375; PMID: 10409699
   PubMed Web of Science ®Google Scholar
• Papac DI, Briggs JB, Chin ET, Jones AJS. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. Glycobiology 1998; 8:445 - 54; http://dx.doi.org/10.1093/glycob/8.5.445; PMID: 9597542
   PubMed Web of Science ®Google Scholar
• Keck RG, Briggs JB, Jones AJS. Oligosaccharide release and MALDI-TOF MS analysis of N-linked carbohydrate structures from glycoproteins. Methods Mol Biol 2005; 308:381 - 96; PMID: 16082050
   PubMedGoogle Scholar
• Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol 2000; 164:4178 - 84; PMID: 10754313
   PubMed Web of Science ®Google Scholar
• Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644 - 52; http://dx.doi.org/10.1021/bp050228w; PMID: 16321047
   PubMed Web of Science ®Google Scholar
• Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995; 32:1311 - 8; http://dx.doi.org/10.1016/0161-5890(95)00118-2; PMID: 8643100
   PubMed Web of Science ®Google Scholar